false 0001831868 0001831868 2026-11-20 2026-11-20 0001831868 icu:CommonStockCustomMember 2026-11-20 2026-11-20 0001831868 icu:Warrants250WarrantsExercisableForOneShareOfCommonStockFor2875PerShareCustomMember 2026-11-20 2026-11-20
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

FORM 8-K

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 20, 2026
 
SeaStar Medical Holding Corporation
 
(Exact name of Registrant as Specified in Its Charter)
 
 
 
Delaware
001-39927
85-3681132
(State or Other Jurisdiction
(Commission File Number)
(IRS Employer
of Incorporation)
 
Identification No.)
3513 Brighton Blvd,
   
Suite 410
   
Denver, Colorado
 
80216
(Address of Principal Executive Offices)
 
(Zip Code)
 
 
Registrant’s Telephone Number, Including Area Code: 844 427-8100
 
(Former Name or Former Address, if Changed Since Last Report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
   
Trading
   
Title of each class
 
Symbol(s)
 
Name of each exchange on which registered
Common Stock par value $0.0001 per share
 
ICU
 
The Nasdaq Stock Market LLC
Warrants, 250 warrants exercisable for one share of Common Stock for $2,875 per share
 
ICUCW
 
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
Item 3.01  Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
 
On November 20, 2026, SeaStar Medical Holding Corporation (the “Company”) received a letter (the “Notice”) from the  Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that based on information provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market with a market value of listed securities of less than $35 million and annual net income of less than $500,000 to maintain a minimum of $2.5 million in stockholder’s equity for continued listing (the “Stockholders’ Equity Requirement”).
 
In accordance with Nasdaq rules, the Company was provided 45 calendar days, or until January 4, 2027, to submit a plan to regain compliance with the Stockholders’ Equity Requirement (the “Compliance Plan”). The Company plans to submit a Compliance Plan. If the Compliance Plan is determined to be acceptable to the Staff, the Staff would have the discretion to grant the Company an extension of 180 calendar days from the date of the Notice to regain compliance with the Stockholders’ Equity Requirement. There can be no assurance that the Compliance Plan will be accepted or that, if it is, the Company will be able to regain compliance. The Notice has no immediate effect on the Company’s continued listing on The Nasdaq Capital Market, subject to the Company’s compliance with other continued listing requirements. If the Staff does not accept the Compliance Plan, the Staff will provide written notification to the Company that the Compliance Plan has been rejected and that the Common Stock is subject to delisting. At that time, the Company may appeal the Staff’s determination to a Nasdaq Hearing Panel.
 
 
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
SeaStar Medical Holding Corporation
   
By:
/s/ Eric Schlorff
Date:
November 20, 2026
Name:
Eric Schlorff
   
Title:
Chief Executive Officer